Yu, Jiayi

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Tang, B., Yan, X., Sheng, X., Si, L., Cui, C., Kong, Y., Mao, L., Lian, B., Bai, X., Wang, X., et al. (2019) · Journal of Hematology & Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 169

The kinase TBK1 controls IgA class switching by negatively regulating noncanonical NF-κB signaling

Jin, J., Xiao, Y., Chang, J.-H., Yu, J., Hu, H., Starr, R., Brittain, G. C., Chang, M., Cheng, X., & Sun, S.-C. (2012) · Nature Immunology

NF-κB Signaling PathwaysT-cell and B-cell Immunology

Cited by 136

Regulation of T-cell activation and migration by the kinase TBK1 during neuroinflammation

Yu, J., Zhou, X., Chang, M., Nakaya, M., Chang, J.-H., Xiao, Y., William Lindsey, J., Dorta-Estremera, S., Cao, W., Zal, A., et al. (2015) · Nature Communications

T-cell and B-cell ImmunologyPsoriasis: Treatment and Pathogenesis

Cited by 118

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

Yu, J., Yan, J., Guo, Q., Chi, Z., Tang, B., Zheng, B., Yu, J., Yin, T., Cheng, Z., Wu, X., et al. (2019) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways

Cited by 100

PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro

Wu, X., Yu, J., Yan, J., Dai, J., Si, L., Chi, Z., Sheng, X., Cui, C., Ma, M., Tang, H., et al. (2018) · Cancer Biology & Therapy

PI3K/AKT/mTOR signaling in cancerMelanoma and MAPK Pathways

Cited by 25